Teixobactin

Drug Profile

Teixobactin

Latest Information Update: 08 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Northeastern University; University of Bonn
  • Developer Northeastern University; NovoBiotic Pharmaceuticals; University of Bonn
  • Class Anti-infectives; Depsipeptides; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Tuberculosis; Vancomycin-resistant enterococcal infections

Most Recent Events

  • 30 Jun 2016 Chemical structure information added
  • 28 Jan 2015 NovoBiotic receives SBIR grant from the the National Institute of Allergy and Infectious Diseases for preclinical development of teixobactin in Gram-positive infections (NovoBiotic Pharmaceuticals website)
  • 22 Jan 2015 Preclinical trials in Gram-positive infections in USA (IV) before January 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top